« Back
Home /
Linperlisib

Linperlisib

Item no.	HY-102031-10mM
Manufacturer	MedChem Express
CASRN	1702816-75-8
Amount	10 mM/1 mL
Quantity options	100 mg 10 mM/1 mL 10 mg 1 mg 25 mg 50 mg 5 mg
Category	Oncology By Cell Type Blastoma Carcinoma Glioma Hematology Leukemia Lymphoma Myeloma Melanoma Sarcoma Cell Biology Cell Status Adenocarcinoma Mesothelioma Autophagy Cardiovascular Research Proliferation Myocardial Infarction Inhibitors & Compound Libraries Small Molecules
Type	Inhibitors
Specific against	other
Purity	98.91
Citations	[1]WO 2015055071 A1
Smiles	CS(=O)(NC1=CC(C2=C3C=C(F)C=C(CN4CCC(C(C)(O)C)CC4)C3=NC(N5CCOCC5)=N2)=CN=C1OC)=O
ECLASS 10.1	32160490
ECLASS 11.0	32160490
UNSPSC	12000000
Alias	YY-20394
Shipping Condition	Room temperature
Available
Manufacturer - Type	Reference compound
Manufacturer - Applications	Cancer-Kinase/protease
Manufacturer - Targets	PI3K
Shipping Temperature	Room Temperature
Storage Conditions	-20°C, 3 years; 4°C, 2 years (Powder)
Molecular Weight	588.69
Product Description	Linperlisib (YY-20394) is a potent, orally bioavailable and selective inhibitor of PI3Kδ extracted from patent WO 2015055071 A1, compound 10; has an IC50 of 6.4 nM[1].
Manufacturer - Research Area	Cancer; Inflammation/Immunology
Solubility	DMSO: 100 mg/mL (ultrasonic)
Manufacturer - Pathway	PI3K/Akt/mTOR
Isoform	PI3Kδ
Clinical information	Phase 4

Note: The presented information and documents (Manual, Product Datasheet, Safety Datasheet and Certificate of Analysis) correspond to our latest update and should serve for orientational purpose only. We do not guarantee the topicality. We would kindly ask you to make a request for specific requirements, if necessary.

All products are intended for research use only (RUO). Not for human, veterinary or therapeutic use.

Request Data Sheet

Request product datasheet

HY-102031-10mM-safety-datasheet.pdf